Published in Postgrad Med J on May 01, 1977
Predicting outcome of paracetamol poisoning by use 14C-aminopyrine breath test. Br Med J (1980) 1.28
Late treatment of paracetamol poisoning with mercaptamine. Br Med J (1978) 1.25
Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J (2002) 1.08
Long-term ingestion of paracetamol and liver disease. J R Soc Med (1980) 0.93
Paracetamol. Postgrad Med J (1980) 0.88
Severe barbiturate and paracetamol overdose: the simultaneous removal of both poisons by haemoperfusion. Postgrad Med J (1980) 0.79
Treatment of acute paracetamol poisoning. Br Med J (1977) 0.75
Non-narcotic analgesics. Problems of overdosage. Drugs (1986) 0.75
Practical stereological methods for morphometric cytology. J Cell Biol (1966) 8.11
Acute liver necrosis following overdose of paracetamol. Br Med J (1966) 4.75
Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J Pharmacol Exp Ther (1973) 4.40
Plasma-paracetamol half-life and hepatic necrosis in patients with paracetamol overdosage. Lancet (1971) 4.40
Acetaminophen-induced hepatic necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp Ther (1973) 3.89
Successful treatment of severe paracetamol overdosage with cysteamine. Lancet (1974) 3.83
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Liver damage and impaired glucose tolerance after paracetamol overdosage. Br Med J (1966) 2.68
Reduction of absorption of paracetamol by activated charcoal and cholestyramine: a possible therapeutic measure. Br Med J (1973) 2.09
Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J Pharm Sci (1972) 2.08
Controlled trial of cysteamine in treatment of acute paracetamol (acetaminophen) poisoning. Lancet (1976) 1.97
Acute poisoning: some myths and misconceptions. Br Med J (1971) 1.94
The gas-liquid chromatographic estimation of phenacetin and paracetamol in plasma and urine. J Pharm Pharmacol (1971) 1.29
Paracetamol overdose in man: relationship between pattern of urinary metabolites and severity of liver damage. Q J Med (1976) 1.03
The development of a blood paracetamol estimation kit. J Int Med Res (1976) 0.93
The paracetamol test-kit in practice. J Int Med Res (1976) 0.90
From animals to man: metabolic considerations. Clin Pharmacol Ther (1974) 0.82
Fatal drug overdosage. J Int Med Res (1976) 0.80
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
An immunoglobulin heavy chain variable region gene is generated from three segments of DNA: VH, D and JH. Cell (1980) 10.35
Two mRNAs can be produced from a single immunoglobulin mu gene by alternative RNA processing pathways. Cell (1980) 9.86
Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens (2004) 8.32
Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 7.43
Cost analysis of early discharge after hip fracture. BMJ (1993) 6.64
Deaths from low dose paracetamol poisoning. BMJ (1998) 6.63
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Anti-tuberculous therapy and acute liver failure. Lancet (1995) 6.27
Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med (2000) 6.07
Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med (2001) 6.05
Papers and originals. Br Med J (1976) 5.90
Mechanisms of fear extinction. Mol Psychiatry (2006) 5.44
Acute liver failure: redefining the syndromes. Lancet (1993) 4.99
Vulnerability genes or plasticity genes? Mol Psychiatry (2009) 4.96
Identification of the receptor component of the IkappaBalpha-ubiquitin ligase. Nature (1998) 4.89
Antibody diversity: somatic hypermutation of rearranged VH genes. Cell (1981) 4.65
Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet (1990) 4.57
Urinary D-glucaric-acid excretion as a test for hepatic enzyme induction in man. Lancet (1971) 4.49
Geobacter sulfurreducens sp. nov., a hydrogen- and acetate-oxidizing dissimilatory metal-reducing microorganism. Appl Environ Microbiol (1994) 4.44
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet (1990) 4.27
Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) (1986) 4.16
Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10
Daily variation of particulate air pollution and poor cardiac autonomic control in the elderly. Environ Health Perspect (1999) 4.07
Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (1972) 3.90
The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 3.78
Activation of the left amygdala to a cognitive representation of fear. Nat Neurosci (2001) 3.71
Inadequate antibody response to hBAg or suppressor T-cell defect in development of active chronic hepatitis. Lancet (1974) 3.61
A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature (1992) 3.59
Extinction of fear-potentiated startle: blockade by infusion of an NMDA antagonist into the amygdala. J Neurosci (1992) 3.40
Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess (2007) 3.40
Structured patient education: the diabetes X-PERT Programme makes a difference. Diabet Med (2006) 3.36
Detection of antibodies directed against a liver-specific membrane lipoprotein in patients with acute and chronic active hepatitis. N Engl J Med (1978) 3.28
Paraquat poisoning: significance of plasma-paraquat concentrations. Lancet (1979) 3.25
Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome. N Engl J Med (1992) 3.24
NHLBI Family Heart Study: objectives and design. Am J Epidemiol (1996) 3.21
Oral methionine in the treatment of severe paracetamol (Acetaminophen) overdose. Lancet (1976) 3.20
High molecular gas fractions in normal massive star-forming galaxies in the young Universe. Nature (2010) 3.18
Lymphocyte cytotoxicity to isolated hepatocytes in chronic active hepatitis. Nature (1974) 3.17
Definition of subchromosomal intervals around the myotonic dystrophy gene region at 19q. Genomics (1989) 3.16
Purification and characterization of human liver-specific membrane lipoprotein (LSP). Clin Exp Immunol (1977) 3.13
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol (1982) 3.09
Mutations that alter the ability of the Escherichia coli cyclic AMP receptor protein to activate transcription. Nucleic Acids Res (1990) 3.08
Presence of a newly described human DNA virus (TTV) in patients with liver disease. Lancet (1998) 3.06
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Household products and poisoning. Br Med J (1978) 3.03
Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet (1973) 2.98
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia (2009) 2.98
Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ (1991) 2.94
More donor organs for transplantation. Elective ventilation proposals. J R Coll Physicians Lond (1993) 2.91
Double dissociation between the involvement of the bed nucleus of the stria terminalis and the central nucleus of the amygdala in startle increases produced by conditioned versus unconditioned fear. J Neurosci (1997) 2.90
Multisystem involvement in chronic liver disease. Studies on the incidence and pathogenesis. Am J Med (1973) 2.88
Determinants of participation in state-of-the-art cancer prevention, early detection/screening, and treatment trials among African-Americans. Cancer Nurs (1993) 2.87
Altered calcium metabolism in epileptic children on anticonvulsants. Br Med J (1971) 2.86
The arthropathy of idiopathic haemochromatosis. Q J Med (1968) 2.85
Hepatitis B virus infection in medical and health care personnel. Br Med J (Clin Res Ed) (1982) 2.85
Liver transplantation after paracetamol overdose. BMJ (1991) 2.81
HIV and surgeons. BMJ (1990) 2.81
New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol (1997) 2.78
Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet (1989) 2.76
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med (1991) 2.75
Liver in Felty's syndrome. Br Med J (1970) 2.75
A primary acoustic startle circuit: lesion and stimulation studies. J Neurosci (1982) 2.73
Trends in sexual behaviour among London homosexual men 1998-2003: implications for HIV prevention and sexual health promotion. Sex Transm Infect (2004) 2.72
Hepatic damage and death from overdose of paracetamol. Lancet (1973) 2.70
Extrahepatic biliary atresia versus neonatal hepatitis. Review of 137 prospectively investigated infants. Arch Dis Child (1976) 2.67
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med (1991) 2.65
Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection. Gastroenterology (1999) 2.62
Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology (1988) 2.60
Treatment of hepatic encephalopathy. N Engl J Med (1997) 2.60
Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord (2000) 2.58
Liver transplantation. Curr Probl Surg (1979) 2.57
A radiation hybrid map of the rat genome containing 5,255 markers. Nat Genet (1999) 2.54
Treatment of fulminant hepatic failure by polyacrylonitrile-membrane haemodialysis. Lancet (1977) 2.53
Mouse Cmu heavy chain immunoglobulin gene segment contains three intervening sequences separating domains. Nature (1980) 2.52
Acute liver failure secondary to hepatic infiltration: a single centre experience of 18 cases. Gut (1998) 2.51
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
A habitable fluvio-lacustrine environment at Yellowknife Bay, Gale crater, Mars. Science (2013) 2.50
Value of a centralised approach in the management of haematemesis and melaena: experience in a district general hospital. Gut (1990) 2.49
The systemic inflammatory response syndrome in acute liver failure. Hepatology (2000) 2.47
Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 2.45
Plasma concentration of amitriptyline and clinical response. Lancet (1972) 2.44
Attentional bias in anxiety and depression: the role of awareness. Br J Clin Psychol (1995) 2.43
Developing and deploying a patient safety program in a large health care delivery system: you can't fix what you don't know about. Jt Comm J Qual Improv (2001) 2.42
Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med (1980) 2.41
Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med (1995) 2.41
1 -Antitrypsin deficiency and neonatal hepatitis. Br Med J (1972) 2.40
The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 2.38